Okamura, Takuro
Hashimoto, Yoshitaka
Hamaguchi, Masahide http://orcid.org/0000-0002-8651-4445
Obora, Akihiro
Kojima, Takao
Fukui, Michiaki
Article History
Received: 6 March 2020
Accepted: 22 June 2020
First Online: 24 July 2020
Ethics approval and consent to participate
: All patients in this sub-analysis of NAGALA study provided their informed consent to participate. The present study was approved by Asahi University hospital’s Ethics Committee. The consent we obtained from study participants was written.
: Not applicable.
: Y. Hashimoto received grants from Japan Society for the Promotion of Science, Asahi Kasei Corporation, MSD K.K., and Fuji Foundation for Protein Research, outside the submitted work. M. Fukui received grants from Japan Society for the Promotion of Science, AstraZeneca plc, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Co. Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corp., Novo Nordisk Pharma Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The authors declare that although they are affiliated with a department that is supported financially by pharmaceutical company, the authors received no current funding for this study, and this does not alter their adherence to all the journal policies on sharing data and materials. The other authors have nothing to disclose.